Suppr超能文献

[具有原发性胃肠道表现的结外非霍奇金淋巴瘤病例史]

[Case histories of extranodal non-Hodgkin's lymphomas with primary gastrointestinal appearance].

作者信息

Buda F, Buda C, La Torre F, Simon G, Binotto F, Bellomo R, Russo F, Croatto T, Duchi M, Mandoliti G

机构信息

Ospedale Civile S. Maria dei Battuti, Regione Friuli-Venezia Giulia--USL 9, Sanvitese.

出版信息

Minerva Chir. 1993 Apr 15;48(7):325-30.

PMID:8327178
Abstract

Authors refer results obtained in 24 cases of primary NHL of gastrointestinal tract. These cases were observed in the period 1981-1990. All cases can be included as primary extranodal lymphomas satisfying criteria of the literature. Sixty-six per cent (16/24) had a gastric localization half cases were centrocytic-centroblastic lymphomas followed by immunoblastic, centroblastic, follicular centrocytic-centroblastic and lymphocytic-well-differentiated. In intestinal localisation (34% of cases), the most represented was lymphocytic poor-differentiated, followed by mixed centrocytic lymphoma. Therapeutic strategy was: surgery in all patients followed by chemotherapy (CHOP 14/24) or by radiotherapy plus chemotherapy (8/24). Surgery alone was adopted in 2 out 24 patients. Patients who received radiotherapy plus chemotherapy had a sandwich treatment (CVP = 4/8, CHOP = 4/8) consisting of splint course of 3 cycles followed by radiotherapy and completed with other 3 drugs cycles. Sixteen out 24 patients were valuable (4 patients were lost during the follow-up due to problems other than the disease; 4 patients are still under treatment). In the 16 valuable patients we had a complete remission (CR) with a median free-disease survival of 82 months (range: 12-116 months) by means of the primary treatment. Four out 16 patients relapsed. In these patients the free-disease survival was range 8-108 months. All patients reached a second CR by means of chemotherapy (CCNU + VIP16) or radiotherapy. No cases of second tumor insorgence was observed.

摘要

作者报告了24例原发性胃肠道非霍奇金淋巴瘤(NHL)的研究结果。这些病例于1981年至1990年期间被观察。所有病例均可被视为符合文献标准的原发性结外淋巴瘤。66%(16/24)的病例发生于胃部,半数病例为中心细胞-中心母细胞性淋巴瘤,其次为免疫母细胞性、中心母细胞性、滤泡性中心细胞-中心母细胞性和高分化淋巴细胞性淋巴瘤。发生于肠道的病例占34%,其中最常见的是低分化淋巴细胞性淋巴瘤,其次是混合性中心细胞淋巴瘤。治疗策略为:所有患者均接受手术治疗,术后接受化疗(CHOP方案,14/24)或放疗加化疗(8/24)。24例患者中有2例仅接受了手术治疗。接受放疗加化疗的患者采用夹心治疗方案(CVP方案4/8,CHOP方案4/8),即先进行3个周期的化疗,然后进行放疗,最后再进行3个周期的化疗。24例患者中有16例可进行评估(4例患者在随访期间因非疾病问题失访;4例患者仍在接受治疗)。在这16例可评估的患者中,通过初始治疗实现了完全缓解(CR),无病生存期的中位数为82个月(范围:12 - 116个月)。16例患者中有4例复发。这些复发患者的无病生存期为8 - 108个月。所有复发患者通过化疗(CCNU + VP16)或放疗均再次达到CR。未观察到第二肿瘤发生的病例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验